Skip to main content

Table 5 Relation between marker (serum chromogranin A) and patient characteristics [181] (note that missing data were not indicated).

From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

 

Serum CgA levels, ng/mL

 
 

Number

Median

Q1 to Q3

Minimum to maximum

P

Subjects

     

   Controls

50

77.4

57.7 to 99.9

28.2 to 196.3

 

   NSCLC patients

88

70.4

37.9 to 114.6

8.7 to 723.8

0.337

Histotype

     

   Adenocarcinoma

22

59.2

35.2 to 85.6

14.8 to 151.2

 

   Squamous

27

80.0

41.0 to 128.6

14.7 to 386.8

 

   Large cell

10

82.1

33.7 to 124.0

11.4 to 217.9

0.465

ECOG PS

     

   0

16

37.7

27.2 to 68.6

8.7 to 103.1

 

   1

59

76.3

43.6 to 119.2

13.9 to 429.7

 

   ≥2

13

102.8

55.8 to 259.4

32.1 to 723.8

0.0005

Stage

     

   IIIB

29

44.9

29.2 to 85.6

13.9 to 259.4

 

   IV

59

82.5

47.1 to 119.2

8.7 to 723.8

0.043

  1. CgA: chromogranin A; ECOG PS: Eastern Cooperative Oncology Group performance status; NSCLC: non-small cell lung cancer; Q1 to Q3: interquartile range.